Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles

JOURNAL ARTICLES 2022, NANOMEDICINES, REVIEWS

 Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles Juan A, Del Mar Noblejas-López M, Arenas-Moreira M, Alonso-Moreno C, Ocaña A. Front Cell Dev Biol. 2022 Feb 3;9:805336. PMID: 35186955; PMCID: PMC8851355 doi:...

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

JOURNAL ARTICLES 2020, NANOMEDICINES, REVIEWS

 Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C. Therapeutics for Breast Cancer Treatment. Int J Mol Sci. 2020 Aug 21;21(17):6018. PMID: 32825618; PMCID: PMC7504566....

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

JOURNAL ARTICLES 2020, NANOMEDICINES, REVIEWS

 An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C. Pharmaceutics. 2020 Aug 25;12(9):802. PMID: 32854255; PMCID: PMC7558516. doi: 10.3390/pharmaceutics12090802.  ...

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

JOURNAL ARTICLES 2021, REVIEWS

 Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment Niza E, Ocaña A, Castro-Osma JA, Bravo I, Alonso-Moreno C. Cancers (Basel). 2021 Jul 6;13(14):3387. doi: 10.3390/cancers13143387.   ...

Clinical considerations for the design of PROTACs in cancer

REVIEWS

 Clinical considerations for the design of PROTACs in cancer C Nieto-Jiménez, EC Morafraile, C Alonso-Moreno, A Ocaña Molecular cancer 21 (1),...

Polylactide Perspectives in Biomedicine: From Novel Synthesis to the Application Performance

REVIEWS

 Polylactide Perspectives in Biomedicine: From Novel Synthesis to the Application Performance C Moya-Lopez, J González-Fuentes, I Bravo, D Chapron, P Bourson, … Pharmaceutics 14 (8),...